This report studies the Heparin market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.
Heparin, a highly sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machine
Heparin API is an anticoagulant (blood thinner) that prevents the formation of blood clots. With the accelerated pace of life and increasing aging population, global morbidity and mortality of cardiovascular and cerebrovascular disease are increased year by year. Heparin API is an efficient solution to those diseases.
Raw materials of Heparin API are mainly porcine intestine, bovine lung and bovine intestine, etc. China pig slaughter amount accounted for more than 50% of the world. It has most abundant raw material resources all over the world.
Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/543899/global-heparin-market
The classification of Heparin includes Heparin Sodium, Heparin Calcium and others, and the proportion of Heparin Sodium in 2016 is about 88%, and the proportion is in decreasing trend from 2012 to 2016.
Heparin is widely used UFH and LMWH. The most proportion of Heparin is used in LMWH, and the proportion in 2016 is 88.9%
Europe is the largest consumption place, with a consumption market share nearly 40% in 2016. Following Europe, United Stated is the second largest consumption place with the consumption market share of 36%.
Market competition is not intense. Hepalink, Bioibérica, Changshan Pharm, etc. are the leaders of the industry, with high-end customers; have been formed in the monopoly position in the industry.
The global Heparin market was 990 million US$ in 2017 and is expected to 1290 million US$ by the end of 2025, growing at a CAGR of 3.4% between 2018 and 2025.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Heparin in these regions, from 2013 to 2025, covering
- North America (United States, Canada and Mexico)
- Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil etc.)
- Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
- Changshan Pharm
- Qianhong Bio-pharma
- Aspen Oss
- King-friend Biochemical Pharmaceutical
- Dongcheng Biochemicals
- Jiulong Biochemicals
- Yino Pharma Limited
By the product type, the market is primarily split into
- Heparin Sodium
- Heparin Calcium
Request Sample Copy of Report@ https://www.qyresearch.com/sample-form/form/543899/global-heparin-market
By the end users/application, this report covers the following segments